Trends in inhaler use and associated carbon footprint: a sales data-based study in Europe
The carbon footprint of inhaler therapy in Europe grew due to an increased use of pMDIs in many European countries. Greater focus on guideline-based controller therapy will potentially improve patient outcomes and decrease SABA over-reliance. Prioritising DPIs or soft mist inhalers when clinically appropriate can lower inhaler greenhouse gas emissions.
Authors
- Christer Janson (ORCID: https://orcid.org/0000-0001-5093-6980)
- Ville A. Vartiainen (ORCID: https://orcid.org/0000-0002-9833-6965)
- Alex Wilkinson (ORCID: https://orcid.org/0000-0002-1808-3663)
- Lauri Lehtimäki (ORCID: https://orcid.org/0000-0003-1586-4998)
- Hanna Hisinger‐Mölkänen (ORCID: https://orcid.org/0000-0003-2293-0279)
Institutions
- Uppsala University (SE)
- University of Helsinki (FI)
- Tampere University (FI)
- Helsinki University Hospital (FI)
- Orion Corporation (Finland) (FI)
- East and North Hertfordshire NHS Trust (GB)
- Tampere University Hospital (FI)
- Tampere University (FI)
Publication Details
- Journal
- BMJ Open Respiratory Research
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1136/bmjresp-2024-002424
- Citations
- 2
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 3.04